Can B (CANB) AI Stock Analysis

• Market Cap: $2.09M
• Dividend Yield: N/A
• Average Volume (3M): 647.88K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.41
• Revenue Growth: -57.73%
• EPS Growth: 82.30%
• Country: US
• Employees: 12
• Sector: Healthcare
• Sector Strength: 41
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.31
• Shares Outstanding: 75,841,990
• 10 Day Avg. Volume: 233,297
• 30 Day Avg. Volume: 647,882
• PEG Ratio: >-0.01
• Price to Book (P/B): -0.49
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 22.45
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

Can B's overall score reflects significant financial struggles, including negative profitability and liquidity issues. Technical analysis shows some long-term stability but short-term weakness. The company's valuation metrics are poor, with negative earnings and no dividend yield, highlighting substantial risks.

Can B Business Overview & Revenue Model

Company Description

Can B Corp (CANB) is a health and wellness company focused on developing and marketing hemp-derived products, including CBD oils, topicals, and other related products. The company operates in the nutraceutical and medical sectors, providing consumers with alternative health solutions aimed at promoting overall well-being. Can B Corp combines innovation with high-quality sourcing to offer a diverse range of products that cater to the growing demand for natural health supplements.

How the Company Makes Money

Can B Corp generates revenue primarily through the sale of its hemp-derived products, which are distributed both through direct-to-consumer channels and wholesale distribution networks. The company leverages e-commerce platforms to reach a broad customer base and enhance its market presence. Key revenue streams include the sale of CBD oils, topicals, and other hemp-based wellness products. Can B Corp also capitalizes on strategic partnerships with retailers and distributors to expand its reach in various markets. Additionally, the company may engage in private label and white label manufacturing for other brands, providing another avenue for revenue generation. Factors contributing to its earnings include the growing consumer interest in natural health alternatives and the legalization and increasing acceptance of hemp-derived products in various regions.

Can B Financial Statement Overview

Summary

Overall, Can B faces severe financial challenges, especially in terms of profitability and liquidity. The company has not only experienced declining revenues but also struggles with high operating losses and negative equity, posing significant risks to its financial health.

Income Statement

The income statement shows significant challenges with negative gross profit margins and consistently negative net income over the years. Revenue has been volatile, evidenced by a sharp decline from 2022 to 2023 and a further drop in TTM data. The company is struggling to achieve profitability, with negative EBIT and EBITDA margins.

Balance Sheet

The balance sheet indicates a weak financial position with negative stockholders' equity as of the latest TTM data, suggesting insolvency risks. The debt-to-equity ratio is not applicable due to negative equity, and the equity ratio is negative. These factors point to significant leverage and instability.

Cash Flow

Cash flow analysis shows some improvement in operating cash flow in TTM, but free cash flow remains negative. The operating cash flow to net income ratio is unhelpful given the negative net income. The company has not generated sufficient cash flow to cover its expenses consistently.

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
981.14K	2.16M	6.69M	4.60M	1.71M	2.31M
	Gross Profit
-1.64M	358.70K	2.61M	2.99M	1.43M	1.71M
	EBIT
-9.60M	-7.49M	-14.17M	-10.27M	-4.36M	-4.58M
	EBITDA
-9.99M	-5.82M	-12.59M	-9.52M	-7.16M	-5.66M
	Net Income Common Stockholders
-12.15M	-9.74M	-14.92M	-12.17M	-5.72M	-4.59M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
29.01K	34.01K	73.19K	449.00K	457.80K	46.54K
	Total Assets
1.34M	10.13M	15.56M	16.47M	5.69M	6.93M
	Total Debt
218.21K	9.18M	9.04M	7.07M	2.08M	132.28K
	Net Debt
189.20K	9.15M	8.97M	6.62M	1.62M	85.74K
	Total Liabilities
217.77K	11.13M	12.86M	10.86M	2.44M	564.67K
	Stockholders Equity
1.12M	-1.00M	2.70M	5.62M	3.26M	6.37M
Cash Flow		Free Cash Flow
246.61K	-1.32M	-3.95M	-8.04M	-2.00M	-4.07M
	Operating Cash Flow
246.61K	-1.30M	-3.95M	-7.32M	-1.95M	-2.41M
	Investing Cash Flow
-9.97K	-84.63K	0.00	-860.79K	-25.25K	-1.66M
	Financing Cash Flow
-259.94K	1.35M	3.57M	8.17M	2.38M	3.31M

Can B Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.03
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CANB, the sentiment is Negative. The current price of 0.03 is below the 20-day moving average (MA) of 0.05, below the 50-day MA of 0.06, and below the 200-day MA of 0.04, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 39.37 is Neutral, neither overbought nor oversold. The STOCH value of 14.57 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CANB.

Can B Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CRON	72 Outperform	$1.15B	16.62	4.61%	―	38.16%	―
CURA	54 Neutral	$867.91M	―	-25.08%	―	-0.11%	11.22%
Sector *	52 Neutral	$5.15B	3.02	-44.64%	2.83%	16.44%	-0.47%
ACB	50 Neutral	$392.97M	30.80	4.78%	―	16.39%	-98.10%
VFF	49 Neutral	$117.95M	―	-14.58%	―	12.09%	-40.10%
TLRY	44 Neutral	$507.64M	―	-31.06%	―	11.22%	-108.58%
CANB	30 Underperform	$2.09M	―	124.11%	―	-57.73%	82.30%

Can B Corporate Events

Can B Corp. Merges with Nascent Pharma Holdings

Can B Corp. underwent a holding company reorganization with Nascent Pharma Holdings, Inc. on October 25, 2024, converting all Can B stock into Nascent stock without tax implications for shareholders. The merger, executed under Florida law, transferred Can B’s assets and operations to Nascent, which now registers its shares under the Securities Exchange Act. While a new trading symbol is pending approval from FINRA, Can B’s equity compensation plans have been adjusted to reflect the transition to Nascent.